Leonteq Securities AG bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,219 shares of the company’s stock, valued at approximately $588,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after buying an additional 609,516 shares during the period. Invesco Ltd. boosted its position in Axsome Therapeutics by 73.3% in the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after buying an additional 419,008 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock valued at $46,662,000 after buying an additional 399,000 shares during the period. Marshall Wace LLP boosted its position in Axsome Therapeutics by 566.5% in the 3rd quarter. Marshall Wace LLP now owns 378,024 shares of the company’s stock valued at $45,911,000 after buying an additional 321,308 shares during the period. Finally, Vanguard Group Inc. boosted its position in Axsome Therapeutics by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after buying an additional 235,626 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have commented on AXSM shares. Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Wolfe Research started coverage on shares of Axsome Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price target for the company. Robert W. Baird raised their price target on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Oppenheimer set a $280.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Finally, Royal Bank Of Canada raised their price target on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $251.26.
Insider Transactions at Axsome Therapeutics
In other news, COO Mark L. Jacobson sold 233 shares of Axsome Therapeutics stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total transaction of $53,165.94. Following the completion of the sale, the chief operating officer directly owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the sale, the director directly owned 47,140 shares of the company’s stock, valued at approximately $7,594,725.40. This trade represents a 34.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 72,628 shares of company stock valued at $12,205,662. Insiders own 20.60% of the company’s stock.
Axsome Therapeutics Price Performance
Axsome Therapeutics stock opened at $235.97 on Friday. The stock has a market cap of $12.14 billion, a P/E ratio of -63.26 and a beta of 0.59. The company has a fifty day simple moving average of $187.84 and a 200-day simple moving average of $171.84. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $236.84. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The firm’s quarterly revenue was up 57.4% on a year-over-year basis. Equities analysts expect that Axsome Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome’s pipeline includes several late-stage and approved product candidates.
Read More
- Five stocks we like better than Axsome Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
